SCHEMBL9948870

SCHEMBL9948870

CC(C)(C)OC(=O)N1CCNC(=O)C12CCNCC2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
MAPK1 P28482 1/20 0.38
CCR5 P51681 2/20 0.35
HSD17B10 Q99714 1/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
BUB1 O43683 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1H2 P55055 3/20 0.31
RXRA P19793 2/20 0.31
NR1H3 Q13133 2/20 0.31
JAK3 P52333 1/20 0.31
CCNC P24863 1/20 0.31
CDK8 P49336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401367 0.89 GRIN2B (0.41) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL2304050 0.86 GRIN2B (0.50) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL19852919 0.85 GRIN2B (0.46) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL21238736 0.83 GRIN2B (0.50) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL10167279 0.83 GRIN2B (0.50) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL22975107 0.82 GRIN2B (0.46) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL21238799 0.82 GRIN2B (0.46) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL24634179 0.81 GRIN2B (0.37) GRIN2BGRIN2CMAPK1CCR5DDB1
SCHEMBL1632144 0.80 MAPK1 (0.41) GRIN2BGRIN2CMAPK1DDB1CRBN
SCHEMBL9949115 0.78 OPRL1 (0.50) MAPK1CCR5HSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes TACR2, TACR1, AGTR1 GRIN2B 310/4885GRIN2C 234/4885MAPK1 2602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.